Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Stock Continues to Climb

PerkinElmer Stock Continues to Climb

Shares in PerkinElmer rose 5.54 percent for the five-day trading period ended Tuesday, continuing a steady ascent over recent weeks. The firm's shares closed at $21.15 on Tuesday, a price not reached since March 29, when PKI's shares rose as high as $21.97. Its low for the last three months was $18, which occurred on June 27. The volume of trading in the firm's shares was also relatively heavy early this week, though no news was announced.

PerkinElmer recently disclosed that it had laid off an undisclosed number of employees as it aims to shift its sales focus from Europe to the Asian market, particularly China and India (see BioCommerce Week 7/14/2005).

Overall, the BCW Index gained .39 percent for the most recent tracking period. The Index trailed the Dow Jones Industrial Average, which gained 1.3 percent, the Nasdaq, which gained 1.4 percent, and the Nasdaq Biotech Index, which rose 2.3 percent for the same timeframe.

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(
July 19 , 2005)
Last Price
(
July 12, 2005)
% Change
Agilent
A
25.95
25.93
0.08
Applied Biosystems
ABI
20.03
20.26
-1.14
Beckman
BEC
64.49
64.05
0.69
Bio-Rad
BIO
58.46
59.8
-2.24
Bruker
BRKR
4.17
4.13
0.97
GE
GE
35.33
35.1
0.66
Harvard Bio
HBIO
3.33
3.28
1.52
Invitrogen
IVGN
85.12
83.88
1.48
Molecular Devices
MDCC
20.93
20.75
0.87
PerkinElmer
PKI
21.15
20.04
5.54
Qiagen
QGEN
12.83
13.15
-2.43
Sigma
SIAL
57.93
57.49
0.77
Strategene
STGN
8.36
8.73
-4.24
Thermo
TMO
27.71
27.98
-0.96
Waters
WAT
39.55
38.9
1.67
Index Average  
32.36
32.23
0.39
The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more